Immix Biopharma, Inc. (IMMX)
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Immix Biopharma, Inc.
NASDAQ:IMMXHealthcare · Biotechnology
-3.76%$7.68
AH$7.95+3.52%vs close
Mkt Cap$636.69M
Float47.65M
O/S82.9M
Vol
$ Vol
RVOL
Inst Own67.9%
SI22.5%
Earnings
Dilution
Financials Summary
Revenue$0
Net Income-$29.44M
Total Assets$104.84M
Free Cash Flow-$24.66M
Debt & Equity
Debt 1%
Equity 99%
Total Debt$1.07M
Total Equity$93.8M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in IMMX's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$104.84M
Liabilities$11.04M
Accounts Receivable$0
Accounts Payable$5.44M
Inventory$0
PP&E (Net)$3.49M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - | - | - |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Margin | - | - | - | - | - | - | - |
| Research and Development | $16.26M | $11.29M | $8.74M | $4.2M | $127K | $248K | $583K |
| Selling, General, and Administrative | $13.7M | $11.38M | $7.41M | $4.02M | $1.23M | $206K | $259K |
| Other | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $29.96M | $22.67M | $16.14M | $8.22M | $1.35M | $454K | $842K |
| Operating Income (EBIT) | -$29.96M | -$22.67M | -$16.14M | -$8.22M | -$1.35M | -$454K | -$842K |
| Operating Margin | - | - | - | - | - | - | - |
| Interest Expense | $0 | $0 | $0 | $497 | $180K | $102K | $110K |
| Interest Income | $556K | $1.02M | $572K | $0 | $0 | $0 | $0 |
| Other Income (Expense) | $556K | $1.02M | $572K | -$497 | -$23.03M | -$676K | -$110K |
| Income Before Tax (EBT) | -$29.4M | -$21.66M | -$15.57M | -$8.22M | -$24.38M | -$1.13M | -$952K |
| Income Tax Expense | $38K | $41K | $26K | $10K | $6K | $18K | $21K |
| Net Income | -$29.44M | -$21.61M | -$15.43M | -$8.23M | -$24.38M | -$1.15M | -$973K |
| Net Income Margin | - | - | - | - | - | - | - |
| Supplementary Data | |||||||
| EPS | -0.89 | -0.76 | -0.89 | -0.59 | -6.64 | -0.15 | -0.29 |
| Diluted EPS | -0.89 | -0.76 | -0.89 | -0.59 | -6.64 | -0.15 | -0.29 |
| Weighted Average OS | 32.97M | 28.29M | 17.34M | 13.89M | 3.67M | 7.77M | 3.38M |
| EBITDA | -$29.59M | -$21.54M | -$15.56M | -$8.22M | -$24.2M | -$452K | -$841K |
| EBITDA Margin | - | - | - | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Assets | |||||||
| Current Assets | |||||||
| Cash and Cash Equivalents | $93.93M | $17.68M | $17.51M | $13.44M | $17.64M | $391K | $734K |
| Short-Term Investments | $6.48M | $0 | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $100.41M | $17.68M | $17.51M | $13.44M | $17.64M | $391K | $734K |
| Accounts Receivable | $0 | $1.97M | $1.17M | $256K | $26K | $127K | $176K |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $151K | $32K | $45K | $78K | $0 | $0 | $0 |
| Total Current Assets | $101.24M | $20.2M | $19.79M | $14.9M | $18.19M | $532K | $933K |
| Long-Term Assets | |||||||
| Property, Plant & Equipment Net | $3.49M | $2.73M | $50K | $4K | $6K | $7K | $10K |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $114K | $20K | $87K | $7K | $0 | $0 | $0 |
| Total Long-Term Assets | $3.6M | $2.75M | $137K | $10K | $6K | $7K | $10K |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $104.84M | $22.95M | $19.93M | $14.91M | $18.19M | $540K | $943K |
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts Payable | $5.44M | $5.39M | $1.43M | $143K | $143K | $252K | $248K |
| Short-Term Debt | $0 | $0 | $0 | $0 | $50K | $4.1M | $4.1M |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $343K | $0 |
| Other Current Liabilities | $0 | $658K | $0 | $0 | $0 | $232K | $0 |
| Total Current Liabilities | $10.11M | $8.69M | $3.72M | $1.27M | $202K | $5.27M | $4.59M |
| Long-Term Liabilities | |||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $0 | $475K | $0 | $0 | $0 |
| Total Long-Term Liabilities | $934K | $1.01M | $0 | $475K | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $11.04M | $9.7M | $3.72M | $1.75M | $202K | $5.27M | $4.59M |
| Stockholders' Equity | |||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $5K | $3K | $2K | $1K | $1K | $338 | $338 |
| Retained Earnings | -$104.46M | -$75.02M | -$53.41M | -$37.99M | -$29.76M | -$5.37M | -$4.22M |
| Comprehensive Income & Other | $60K | -$1K | $135K | $87K | $125K | $132K | $68K |
| Other Stockholders' Equity | $198.25M | $88.27M | $69.81M | $51.14M | $47.74M | $641K | $577K |
| Total Equity | $93.8M | $13.25M | $16.41M | $13.16M | $17.99M | -$4.73M | -$3.65M |
| Minority Interest | $0 | $0 | -$202K | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $104.84M | $22.95M | $20.13M | $14.91M | $18.19M | $540K | $943K |
| Supplementary Data | |||||||
| Total Debt | $1.07M | $1.07M | $0 | $0 | $50K | $4.1M | $4.1M |
| Net Debt | -$92.86M | -$16.61M | -$17.51M | -$13.44M | -$17.59M | $3.71M | $3.37M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Operating Activities | |||||||
| Net Income | -$29.44M | -$21.7M | -$15.6M | -$8.23M | -$24.38M | -$1.15M | -$973K |
| Depreciation & Amortization | $365K | $115K | $5K | $2K | $2K | $2K | $1K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $2.44M | $3.02M | $2.57M | $624K | $219K | $0 | $0 |
| Changes in Working Capital: | |||||||
| Accounts Receivable | $2.06M | -$972K | -$893K | -$236K | $98K | $58K | -$36K |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $36K |
| Accounts Payable | $1.03M | $4.4M | $2.43M | $1.13M | -$106K | -$4K | $123K |
| Other Working Capital | -$385K | $537K | $112K | -$700K | -$383K | $111K | $59K |
| Total Working Capital Change | $2.7M | $3.97M | $1.65M | $195K | -$391K | $166K | $182K |
| Other Non-Cash Items | $0 | $0 | $0 | $0 | $22.96M | $575K | $0 |
| Net Cash from Operating | -$23.93M | -$14.6M | -$11.37M | -$7.41M | -$1.59M | -$405K | -$790K |
| Investing Activities | |||||||
| Capital Expenditures | -$733K | -$1.18M | -$52K | $0 | -$802 | $0 | -$7K |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | -$6.48M | $0 | $0 | $0 | $0 | $0 | $0 |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Investing | -$7.21M | -$1.18M | -$52K | $0 | -$802 | $0 | -$7K |
| Financing Activities | |||||||
| Debt Repaid | - | - | - | - | -$200K | - | -$1.05M |
| Common Stock Issuance | $107.39M | $15.95M | $15.7M | $3.39M | $18.65M | $0 | $0 |
| Common Stock Repurchases | $0 | $0 | $0 | -$100K | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | $0 | -$232K | -$7K | $0 | $0 | $0 |
| Net Cash from Financing | $107.39M | $15.95M | $15.46M | $3.23M | $18.85M | $0 | $1.05M |
| Forex Effect | $4K | -$4K | $33K | -$32K | -$5K | $62K | $19K |
| Net Change in Cash | $76.25M | $172K | $4.07M | -$4.21M | $17.25M | -$343K | $272K |
| Supplementary Data | |||||||
| Operating Cash Flow | -$23.93M | -$14.6M | -$11.37M | -$7.41M | -$1.59M | -$405K | -$790K |
| Capital Expenditure | -$733K | -$1.18M | -$52K | $3 | -$802 | $0 | -$7K |
| Free Cash Flow | -$24.66M | -$15.77M | -$11.42M | -$7.41M | -$1.59M | -$405K | -$797K |
| Cash at Beginning | $17.68M | $17.51M | $13.44M | $17.64M | $391K | $734K | $462K |
| Cash at End | $93.93M | $17.68M | $17.51M | $13.44M | $17.64M | $391K | $734K |